367 related articles for article (PubMed ID: 19846286)
1. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.
Massanari M; Holgate ST; Busse WW; Jimenez P; Kianifard F; Zeldin R
Respir Med; 2010 Feb; 104(2):188-96. PubMed ID: 19846286
[TBL] [Abstract][Full Text] [Related]
2. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
3. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
4. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
[TBL] [Abstract][Full Text] [Related]
5. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
6. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
7. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
Massanari M; Kianifard F; Zeldin RK; Geba GP
Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
10. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2006 Apr; (2):CD003559. PubMed ID: 16625585
[TBL] [Abstract][Full Text] [Related]
11. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
[TBL] [Abstract][Full Text] [Related]
12. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
[TBL] [Abstract][Full Text] [Related]
13. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.
Noga O; Hanf G; Kunkel G
Int Arch Allergy Immunol; 2003 May; 131(1):46-52. PubMed ID: 12759489
[TBL] [Abstract][Full Text] [Related]
14. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
[TBL] [Abstract][Full Text] [Related]
16. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
17. Anti-IgE for chronic asthma.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
[TBL] [Abstract][Full Text] [Related]
18. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
Foroughi S; Foster B; Kim N; Bernardino LB; Scott LM; Hamilton RG; Metcalfe DD; Mannon PJ; Prussin C
J Allergy Clin Immunol; 2007 Sep; 120(3):594-601. PubMed ID: 17765756
[TBL] [Abstract][Full Text] [Related]
19. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on omalizumab in allergic asthma.
Bang LM; Plosker GL
BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
